Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM862 + Chemo in Advanced Ovarian Cancer
NCT00017303Phase 2Unknown
- Sponsor
- Cytran
- Start
- Jan 2001
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oglufanide disodium in ovarian epithelial cancer and primary peritoneal carcinoma (PPC) (3 arms), sponsored by Cytran. Primary endpoint: Complete pathologic response rate at second-look surgery. Status: unknown.
02
Drugs
oglufanide disodium
03
Conditions
ovarian epithelial cancerprimary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00017303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00017303.